The futility of adverse drug event reporting systems for monitoring known safety issues: A case study of myocardial infarction with rofecoxib and other drugs

Artificial intelligence and pharmacovigilance: What is happening, what could happen and what should happen?

(2023) Andrew Bate et al.   Health Policy and Technology

Digital biomarkers for post-licensure safety monitoring

(2022) Luis Garcia-Gancedo et al.   DRUG DISCOVERY TODAY

Acute myocardial infarction: Development and application of an ICD-10-CM-based algorithm to a large U.S. healthcare claims-based database

(2021) Patrick Saunders-Hastings et al.   PLoS One

The cost of pharmacovigilance: a time and motion study of an adverse drug reaction program

(2021) Gina B McLachlan et al.   INTERNATIONAL JOURNAL OF PHARMACY PRACTICE

Pharmacovigilance in Crisis: Drug Safety at a Crossroads

(2018) John Price   CLINICAL THERAPEUTICS

Can Electronic Health Records Databases Complement Spontaneous Reporting System Databases? A Historical-Reconstruction of the Association of Rofecoxib and Acute Myocardial Infarction

(2018) Vaishali K. Patadia et al.   Frontiers in Pharmacology

Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program

(2012) Sarah L. Cutrona et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety

(2012) Melissa A. Robb et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY